Cite
WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study.
MLA
Ben Salah, Afif, et al. “WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania Major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study.” PLoS Neglected Tropical Diseases, vol. 3, no. 5, May 2009, pp. 1–9. EBSCOhost, https://doi.org/10.1371/journal.pntd.0000432.
APA
Ben Salah, A., Buffet, P. A., Morizot, G., Ben Massoud, N., Zâatour, A., Ben Alaya, N., Haj Hamida, N. B., Ahmadi, Z. E., Downs, M. T., Smith, P. L., Dellagi, K., & Grögl, M. (2009). WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study. PLoS Neglected Tropical Diseases, 3(5), 1–9. https://doi.org/10.1371/journal.pntd.0000432
Chicago
Ben Salah, Afif, Pierre A. Buffet, Gloria Morizot, Nathalie Ben Massoud, Amor Zâatour, Nissaf Ben Alaya, Nabil Bel Haj Hamida, et al. 2009. “WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania Major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study.” PLoS Neglected Tropical Diseases 3 (5): 1–9. doi:10.1371/journal.pntd.0000432.